









市場行情
/
股票
/
nasdaq-kros
/

Keros Therapeutics Inc

KROS

21.030USD

-0.330-1.54%

收盤 12/26, 16:00（美東）報價延遲15分鐘

854.49M總市值

13.21本益比TTM



Keros Therapeutics Inc

21.030

-0.330-1.54%

概覽公司財務分析

概覽

公司

財務

分析

關於 Keros Therapeutics Inc 公司

Keros Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing novel therapeutics to treat a range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (TGF-B), family of proteins. Its lead product candidate, KER-050, is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, and in patients with myelofibrosis. Its product candidate, KER-012, is being developed for the treatment of pulmonary arterial hypertension, or PAH, and for the treatment of cardiovascular disorders. Its product candidate, KER-065, is being developed for the treatment of obesity and for the treatment of neuromuscular diseases. KER-050 is designed to raise red blood cell and platelet production by inhibiting the signaling of a subset of the TGF-B family of proteins to promote hematopoiesis.

Keros Therapeutics Inc簡介



公司代碼KROS

公司名稱Keros Therapeutics Inc

上市日期Apr 08, 2020

CEOSeehra (Jasbir)

員工數量169

證券類型Ordinary Share

年結日Apr 08

公司地址1050 Waltham Street, Suite 302

城市LEXINGTON

上市交易所NASDAQ OMX - NASDAQ BASIC

國家United States of America

郵編02421

電話16173146297

網址https://www.kerostx.com/

公司代碼KROS

上市日期Apr 08, 2020

CEOSeehra (Jasbir)

Keros Therapeutics Inc公司高管



名稱

名稱/職務

職務

持股

持股變動

Dr. Jasbir Seehra, Ph.D.

President, Chief Executive Officer, Director

392.72K

+29.94%

Mr. Julius Knowles

Independent Director

6.44K

+440.81%

Mr. Jean-Jacques Bienaime ,

Independent Chairman of the Board

5.45K

+2625.00%

Dr. Carl L. Gordon, Ph.D.

Independent Director

5.25K

Mr. Nima Farzan

Independent Director

5.25K

Dr. Mary Ann Gray, Ph.D.

Independent Director

5.25K

Mr. Justin Frantz

Head of Investor Relations

Mr. Keith C. Regnante

Chief Financial Officer

-100.00%

Dr. Alpna Hansraj Seth, Ph.D.

Independent Director

Dr. Lorena Lerner, Ph.D.

Chief Scientific Officer

名稱

名稱/職務

職務

持股

持股變動

Dr. Jasbir Seehra, Ph.D.

President, Chief Executive Officer, Director

392.72K

+29.94%

Mr. Julius Knowles

Independent Director

6.44K

+440.81%

Mr. Jean-Jacques Bienaime ,

Independent Chairman of the Board

5.45K

+2625.00%

Dr. Carl L. Gordon, Ph.D.

Independent Director

5.25K

Mr. Nima Farzan

Independent Director

5.25K

Dr. Mary Ann Gray, Ph.D.

Independent Director

5.25K

收入明細

由於公司未披露，未能獲取相關數據

由於公司未披露，未能獲取相關數據

業務

地區

由於公司未披露，未能獲取相關數據

股東統計

更新時間: 11月20日週四

持股股東

股東類型

持股股東

佔比

Madison Avenue Partners LP

8.89%

The Vanguard Group, Inc.

8.89%

Tang Capital Management, LLC

7.94%

BlackRock Institutional Trust Company, N.A.

7.73%

Western Standard, LLC

7.19%

其他

59.37%

持股股東

佔比

Madison Avenue Partners LP

8.89%

The Vanguard Group, Inc.

8.89%

Tang Capital Management, LLC

7.94%

BlackRock Institutional Trust Company, N.A.

7.73%

Western Standard, LLC

7.19%

其他

59.37%

股東類型

持股股東

佔比

Hedge Fund

44.98%

Investment Advisor

28.60%

Investment Advisor/Hedge Fund

23.28%

Research Firm

4.64%

Venture Capital

2.82%

Private Equity

2.64%

Corporation

1.89%

Individual Investor

1.79%

Pension Fund

1.13%

機構持股



更新時間: 10月1日週三

報告期間

機構數

持股數

持股佔比

持股變動

2025Q3

385

41.03M

124.11%

-17.81M

2025Q2

392

46.16M

114.02%

-7.54M

2025Q1

394

39.41M

98.81%

-8.43M

2024Q4

366

43.10M

106.25%

-873.01K

2024Q3

351

43.05M

114.83%

+404.61K

2024Q2

337

39.69M

109.09%

-4.15M

2024Q1

332

39.81M

110.03%

+1.08M

2023Q4

310

34.40M

109.87%

-229.62K

2023Q3

303

31.04M

104.70%

-2.97M

2023Q2

305

30.88M

104.58%

-2.59M

股東持股明細



名稱

持股數

佔比

持股變動

變動比例

公告日期

Madison Avenue Partners LP

2.69M

6.63%

+77.06K

+2.95%

Jun 30, 2025

The Vanguard Group, Inc.

2.62M

6.45%

+53.89K

+2.10%

Jun 30, 2025

Tang Capital Management, LLC

1.42M

3.49%

+318.98K

+29.00%

Jun 30, 2025

BlackRock Institutional Trust Company, N.A.

2.39M

5.88%

-118.03K

-4.71%

Jun 30, 2025

Western Standard, LLC

1.53M

3.78%

+1.40M

+1037.68%

Jun 30, 2025

D. E. Shaw & Co., L.P.

1.30M

3.19%

+34.25K

+2.71%

Jun 30, 2025

State Street Investment Management (US)

1.38M

3.41%

+81.72K

+6.27%

Jun 30, 2025

Nantahala Capital Management, LLC

1.62M

3.99%

+113.90K

+7.56%

Jun 30, 2025

持股ETF



更新時間: 12月6日週六

機構名稱

佔比

Virtus LifeSci Biotech Clinical Trials ETF

0.76%

ALPS Medical Breakthroughs ETF

0.26%

State Street SPDR S&P Biotech ETF

0.21%

Federated Hermes MDT Small Cap Core ETF

0.12%

Direxion Daily S&P Biotech Bull 3X Shares

0.1%

ProShares Ultra Nasdaq Biotechnology

0.09%

WisdomTree US SmallCap Quality Growth Fund

0.07%

Goldman Sachs ActiveBeta US Small Cap Equity ETF

0.06%

Invesco Nasdaq Biotechnology ETF

0.06%

iShares Biotechnology ETF

0.05%

Virtus LifeSci Biotech Clinical Trials ETF

佔比0.76%

ALPS Medical Breakthroughs ETF

佔比0.26%

State Street SPDR S&P Biotech ETF

佔比0.21%

Federated Hermes MDT Small Cap Core ETF

佔比0.12%

Direxion Daily S&P Biotech Bull 3X Shares

佔比0.1%

ProShares Ultra Nasdaq Biotechnology

佔比0.09%

WisdomTree US SmallCap Quality Growth Fund

佔比0.07%

Goldman Sachs ActiveBeta US Small Cap Equity ETF

佔比0.06%

Invesco Nasdaq Biotechnology ETF

佔比0.06%

iShares Biotechnology ETF

佔比0.05%

分紅派息



近5年累計派現 0.00 美元

公告日期

分紅計劃

股權登記日

現金發放日

除權除息日

暫無數據

拆合股



公告日期

類型

比率

暫無數據

公告日期

類型

比率

暫無數據

常見問題

Keros Therapeutics Inc的前五大股東是誰？



Keros Therapeutics Inc的前五大股東如下：
Madison Avenue Partners LP
持有股份：2.69M
佔總股份比例：6.63%。
The Vanguard Group, Inc.
持有股份：2.62M
佔總股份比例：6.45%。
Tang Capital Management, LLC
持有股份：1.42M
佔總股份比例：3.49%。
BlackRock Institutional Trust Company, N.A.
持有股份：2.39M
佔總股份比例：5.88%。
Western Standard, LLC
持有股份：1.53M
佔總股份比例：3.78%。